Codein

Quick links to important sections

Codein

Method of action: Antitussive Opioid

Treatment option: Pain

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Codein

Codeine: A Core Definition and Purpose

Property Description
Active Ingredient Codeine (usually as Phosphate or Sulfate salt)
Form Tablet, capsule, oral solution (liquid)
Pharmacological Class Opioid Agonist (Mild Opioid Analgesic)
Common Use Pain relief (mild-to-moderate), Cough suppression
Origin Natural Opioid Alkaloid (derived from opium poppy)

Codeine is a globally utilized oral medication primarily categorized as an opioid agonist, clinically recognized for its reliable efficacy in managing pain and suppressing coughs. It is formally recognized under the International Nonproprietary Name (INN) codeine and its salt forms. The drug is consistently classified as a mild or weak opioid analgesic and is administered orally for systemic effect. Its use is subject to prescription control (Rx status) due to its opioid nature, which is a key differentiator from over-the-counter pain relievers.

Origin, Composition, and General Use

Codeine is an opiate—a naturally occurring alkaloid—derived primarily from the opium poppy (Papaver somniferum), distinguishing it as a pharmaceutical agent with a long history of clinical use. Chemically, codeine is a methylated derivative of morphine, a structural difference that results in its comparatively milder analgesic action. The product used in commercial pharmaceutical forms is highly purified.

The two main therapeutic applications of codeine are analgesia (pain relief) and its role as an antitussive (cough suppressant). Codeine has been an established treatment for cough and mild pain for many years, providing a reliable option for short-term relief. For instance, a common use scenario involves managing the discomfort of a severe headache or persistent, dry cough that prevents sleep. These are accepted and intended uses within medical practice.

Regulatory References

  1. NIH MedlinePlus Codeine Drug Information

What side effects are possible with Codein?

Codeine's officially documented safety profile centers on effects related to the central nervous and gastrointestinal systems, which is characteristic of opioid agonists. Regulatory classifications describe these effects according to frequency and the affected organ system. Effects for which frequency is "Not Known" are also documented, spanning immune, blood, and nervous system disorders.

System/Organ Class (SOC) Common Adverse Reactions (Official Labeling)
Nervous System Disorders Drowsiness, Light-headedness, Dizziness, Sedation
Gastrointestinal Disorders Nausea, Vomiting, Constipation
Skin Disorders Sweating
Respiratory Disorders Shortness of breath

A primary safety concern involves serious, life-threatening respiratory depression, which is explicitly noted to require close observation, particularly upon the initiation of therapy or following a dose increase. Codeine also exposes users to the inherent risk of opioid addiction, abuse, and misuse. Prolonged use is associated with the risk of developing physical dependence and potential Adrenal Insufficiency.

Regulatory authorities impose strict population-specific safety considerations. Codeine is contraindicated in all children younger than 12 years of age for any use and in individuals of any age known to be CYP2D6 ultra-rapid metabolizers due to the risk of toxicity. Use is not recommended for breastfeeding mothers, and caution is required for the elderly or those with hepatic or renal impairment.

Overdose and Emergency Response

The official regulatory documentation for codeine describes an overdose profile centered on severe Central Nervous System (CNS) and respiratory depression. Documented overdose presentations range from profound somnolence to stupor and coma. The most critical, life-threatening manifestation is severe respiratory depression, leading to shallow breathing, hypoxia, and the potential for respiratory arrest. Clinical signs often documented include miosis (pinpoint pupils), skeletal muscle flaccidity, and cardiovascular events such as hypotension and circulatory collapse. These severe outcomes, which may lead to death, necessitate immediate action.

Because of the documented risk of life-threatening events, emergency medical care is required upon any suspicion of overdose, and affected individuals must seek immediate medical attention. Management, as described in regulatory sources, includes providing symptomatic and supportive treatment, establishing a patent airway, and often utilizing assisted or controlled ventilation. The specific opioid antagonist Naloxone is the documented intervention to reverse acute opioid-induced respiratory depression. Continuous observation and hospital monitoring are necessary due to the risk of symptom recurrence. Regulatory labels explicitly note pediatric patients and the elderly as high-risk populations for increased sensitivity and severe toxicity.

Therapeutic Uses of Codein

What Codeine Treats: Main Uses and Benefits


The medication is used across domains where additional symptomatic support is needed to address symptoms related to physical discomfort and heightened physiological activity. Codeine is commonly used across conditions presenting with episodic or fluctuating manifestations, including symptoms related to physical discomfort, persistent, dry cough, and symptoms of increased bowel frequency.

Codeine is applied in scenarios where symptoms intensify and supportive relief is needed when additional management of discomfort is required. The medication is helpful in situations requiring additional symptomatic assistance, and generally contributes to easing the overall symptom load, which is relevant in clinical settings that involve acute or unstable symptom patterns.

Quick Fact: Relief for Acute Discomfort
Codeine is relevant for easing symptoms related to physical discomfort that is generally mild-to-moderate in intensity, and may assist with maintaining functional stability.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Codeine Use

Codeine use is strictly defined by government regulatory agencies through a set of absolute prohibitions and restrictions based on patient status, age, and existing conditions.

Category Official Regulatory Status
Populations Contraindicated (Must Not Use) Children younger than 12 years of age (all uses). Women who are breastfeeding. Individuals known or suspected to be CYP2D6 ultra-rapid metabolizers. Patients with significant respiratory depression or acute bronchial asthma.
Age-Related Rules Contraindicated under 12 years. Contraindicated in children and adolescents (younger than 18) following tonsillectomy or adenoidectomy. Permitted only for acute moderate pain in adolescents (12–18 years) when other non-opioids are ineffective.
Physiological Restrictions Not recommended during the third trimester of pregnancy due to risk of neonatal withdrawal. Caution advised for use in older adults (geriatric population), often requiring a reduced starting dose.
Condition-Specific Rules Contraindicated in patients with gastrointestinal obstruction (e.g., paralytic ileus). Caution is mandated for patients with severe renal impairment or hepatic impairment, as well as those with increased intracranial pressure.

These official eligibility statements mandate who can and cannot use the medicine, primarily excluding vulnerable populations due to the risk of life-threatening respiratory depression. The constraints are categorized by genetic, age, and physiological factors, ensuring use remains within established safety parameters defined by regulatory documents.

What should I know about interactions with other medicines?

Codeine Interactions with other medicines and products

Codeine is a prodrug whose efficacy and safety are significantly influenced by interactions affecting its metabolism and central nervous system (CNS) activity. It is primarily converted to its active metabolite, morphine, by the Cytochrome P450 2D6 (CYP2D6) enzyme.


Pharmacokinetic Interactions (Metabolism)

  • CYP2D6 Inhibitors (e.g., certain antidepressants like paroxetine, fluoxetine, or bupropion) can decrease the conversion of codeine to morphine. This action may lead to a reduced analgesic effect or treatment failure.
  • CYP3A4 Inhibitors (e.g., macrolide antibiotics, certain antifungals) or CYP3A4 Inducers (e.g., rifampin, phenytoin) may alter codeine concentrations or the formation of its inactive metabolite, norcodeine, which requires careful clinical consideration.

Pharmacodynamic Interactions (CNS and Serotonin)

  • CNS Depressants (including benzodiazepines, other opioids, sedatives, and alcohol) pose a risk of life-threatening respiratory depression, profound sedation, coma, and death due to additive depressant effects. Concomitant use should be reserved for cases where alternatives are inadequate, using minimum dosage and duration.
  • Monoamine Oxidase Inhibitors (MAOIs) are contraindicated for concurrent use or within 14 days of discontinuing an MAOI, due to the risk of severe, potentially fatal interaction.
  • Serotonergic Drugs (e.g., SSRIs, SNRIs) may increase the risk of serotonin syndrome, a potentially life-threatening condition. Discontinuation of codeine is required if this syndrome is suspected.

Other Interactions and Restrictions

  • Use with mixed agonist/antagonist or partial agonist opioid analgesics may reduce codeine's analgesic effect or precipitate withdrawal symptoms, and should be avoided.
  • Codeine is contraindicated in patients who are known to be CYP2D6 ultra-rapid metabolizers due to the risk of life-threatening morphine toxicity, including respiratory depression.

Mechanism of Action

Codeine functions as a prodrug that undergoes O-demethylation primarily within the liver via the Cytochrome P450 2D6 (CYP2D6) enzyme to form its active metabolite, morphine. Morphine subsequently acts as an agonist at opioid receptors distributed throughout the central nervous system (CNS) and the gastrointestinal tract.

The principal biological target is the mu-opioid receptor (MOR), a G-protein coupled receptor. Agonist binding to the MOR initiates intracellular signaling via Galphai protein coupling. This interaction leads to the inhibition of adenylyl cyclase, resulting in a decrease in intracellular cyclic adenosine monophosphate (cAMP) levels. Downstream consequences include the inhibition of voltage-gated calcium channels and the opening of G protein-coupled inwardly rectifying potassium (GIRK) channels.

These cellular actions cause hyperpolarization of the neuronal membrane and a reduction in neuronal excitability. The overall system-level physiological consequence involves the modulation of signal transduction along the afferent nociceptive pathways, leading to a diminished transmission of incoming neural signals within the CNS and altered cough reflex activity in the medulla.

Dosage and Administration Information

Official Administration Guidelines and Dosage Principles

Codeine is generally administered via the oral route in the form of immediate-release tablets, capsules, or an oral solution.

Standard guidelines establish specific dose ranges and frequency patterns for its use. For analgesia in adults, the usual immediate-release dose is 15 mg to 60 mg, which may be taken up to every 4 hours as needed. The maximum daily dose for immediate-release formulations is defined and should not be exceeded.

Indication Adult Dose Range Frequency Pattern Duration Principle
Analgesia (Pain) 15 mg to 60 mg Up to every 4 hours (PRN) Shortest possible duration
Antitussive (Cough) 7.5 mg to 30 mg Every 4 to 6 hours (IR) Acute short-term use

Procedural and Population Constraints

Accurate measurement is mandated for liquid codeine formulations. Patients must use a calibrated measuring device (syringe or cup) provided with the product, and household spoons are strictly advised against to prevent inaccurate dosing.

Standard clinical practice includes specific age restrictions, contraindicating the use of codeine for any indication in children younger than 12 years of age. Furthermore, treatment for acute symptoms, such as pain, is generally restricted to the lowest effective dosage for the shortest possible duration, and gradual dose reduction (tapering) is necessary upon discontinuation after prolonged use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Codeine

Evidence for Use in Mild-to-Moderate Acute Pain

Research for codeine was studied for short-term, acute pain, such as discomfort following minor surgeries. The core evidence comes from Randomized Controlled Trials (RCTs) and meta-analyses that monitor how pain symptoms evolve over the first few hours following a dose. Researchers explored outcomes by measuring changes in pain intensity using standardized patient-reported scales. A key limitation is the significant variability in how individuals metabolize codeine, meaning results reflect group patterns and not personal outcomes. Long-term findings are not fully established, as most follow-up durations were limited to the immediate term.

Evidence for Use as a Cough Suppressant

Codeine was studied for its application to acute, persistent cough, primarily associated with Upper Respiratory Tract Infections. Research examined this use through RCTs and subsequent systematic reviews that explored outcomes related to objective cough frequency and subjective patient-reported discomfort. Findings were often mixed across various studies, with systematic reviews indicating that the evidence remains limited and heterogeneous, often showing minimal difference when compared to a placebo. Certainty remains low for a significant, consistent action.

Evidence in Special Populations and Uncertainties

The results apply only to the populations studied, with most evidence focusing on adults. Data for certain groups, such as very young children, remain insufficient for use, leading to regulatory restrictions. The most critical overarching uncertainty relates to the aforementioned metabolic variability. Furthermore, evidence quality varies across studies, and for all indications, long-term findings are not fully established, highlighting limited information regarding the durability of any measured changes.

Key Studies & References Variability in Codeine Metabolism and Therapeutic Outcomes

Frequently Asked Questions (FAQ)

Common questions about Codein (FAQ)


Q: How quickly does Codeine start to work after taking it?

According to official pharmacokinetic information, the effect of Codeine on pain relief typically reaches its maximum level, or peak, within approximately two hours after the dose is taken. This time frame reflects how quickly the medicine is processed and begins acting within the body.


Q: How long does the effect of Codeine usually last?

Regulatory documents describing the medicine's activity indicate that the analgesic (pain-relieving) effect typically lasts between four and six hours. This duration guides the recommended frequency for taking the medicine.


Q: What kind of common over-the-counter medicines might interact with Codeine?

Official warnings indicate that Codeine can interact with certain common over-the-counter (OTC) medicines. This primarily includes products that cause drowsiness, like some antihistamines, or those that affect the serotonin system, such as the herbal supplement St. John's wort.


Q: Does taking Codeine with food change how it works?

Official administration information states that Codeine may be taken either with food or just after a meal or snack. Taking it this way may help make it less likely to cause nausea or an upset stomach.


Q: Can Codeine affect your ability to drive or operate machinery?

Because Codeine can cause effects like drowsiness, dizziness, or light-headedness, official prescribing information includes warnings about performing tasks that require mental focus. Official labeling includes warnings against driving a car or operating heavy machinery until the individual knows how the medication affects their alertness.


Q: Is it possible to become dependent on Codeine if I only take it for a short time?

Official regulatory documents state that the risks of addiction, abuse, and misuse are associated with the use of opioid medicines regardless of the dosage or duration. Physical dependence is a risk associated with using the medicine, and official documentation states that a gradual dose reduction (tapering) is necessary upon discontinuation after prolonged use.


Q: What happens if I miss a dose of Codeine?

According to official guidance, if you take Codeine regularly and miss a dose, the guidance generally states that it can be taken as soon as the lapse is remembered. However, if it is almost time for your next scheduled dose, the instruction is to skip the missed dose and return to your regular schedule, rather than taking a double dose.


Q: Are there different forms or strengths of Codeine medicine?

Official drug listings show that Codeine is available in several different pharmaceutical forms. This includes tablets in various strengths, capsules, and an oral liquid solution or syrup.


Q: Does Codeine show up on standard drug tests?

As Codeine is classified as an opioid, it can be detected in body fluids and is often included in standard opiate drug tests. Since Codeine is converted into morphine by the body, both the parent drug and its metabolite are typically detectable for a few days after administration.


Q: Can I take other pain relievers like acetaminophen or ibuprofen with Codeine?

Official information notes that Codeine is often available in fixed combination products with non-opioid pain relievers, such as acetaminophen. Warnings advise against taking Codeine that is already combined with ibuprofen or aspirin at the same time as taking another dose of ibuprofen or aspirin separately.


Q: Can taking Codeine regularly affect my mood?

Official safety information for Codeine lists effects related to the central nervous system (CNS), such as dizziness and drowsiness. Reports of less common effects have included changes in mood, such as feelings of euphoria (extreme happiness) or dysphoria (a state of feeling unwell or unhappy).


Q: Can Codeine interact with herbal supplements?

Official information indicates that it is not possible to assure that all herbal remedies and supplements are safe to take with Codeine. Regulatory information notes that specific herbal supplements, such as St. John’s wort, may interact by affecting how the body processes the medication.


Q: Are there any known interactions between Codeine and caffeine?

Official drug interaction lists typically do not define a major interaction between Codeine and caffeine. However, caution is always advised as individual reactions can vary based on personal sensitivity.


Q: How does the onset of liquid Codeine compare to pill form?

Official labels generally state that the mental effects of Codeine may begin to be felt between 20 and 60 minutes after taking it. However, the regulatory documents do not typically provide a specific comparison of how the onset time of the liquid formulation differs from that of the tablet.


Q: What are the signs of a serious allergic reaction to Codeine?

Official regulatory materials list serious allergic reactions (hypersensitivity) as a possible adverse effect and a contraindication. Official documentation states that symptoms of a serious allergic reaction can include signs such as hives, rash, swelling, or difficulty breathing.


Q: Does the body build up a tolerance to Codeine over time?

Regulatory documents state that the body can develop tolerance to Codeine with continued use. This means that after a period of time, the same dose may become less effective for pain relief.


Q: Why is Codeine often combined with other non-opioid pain relievers?

Codeine is classified as a mild or weak opioid, and it is frequently combined with non-opioid pain relievers like acetaminophen in commercial products. This is done because Codeine is classified as a mild opioid, and the combination aims to provide enhanced pain relief through multiple analgesic mechanisms.

How should Codein be stored and disposed of?

Storage and Disposal Requirements for Codeine

Codeine must be stored under Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions between 15 C and 30 C (59 F and 86 F). The product must be protected from excess moisture and, for some formulations, direct light. The container must be kept tightly closed to maintain product integrity.

Child Safety and Security

As a controlled substance with a high risk of fatal accidental overdose, the medicine must be stored securely and out of the sight and reach of children.

Disposal Instructions

Unused or expired codeine must be disposed of immediately to prevent misuse or accidental ingestion. The regulatory recommendation is to use a drug take-back program or an authorized collection site. If these are unavailable, certain high-risk codeine products may be flushed down the toilet as specified on the FDA's designated flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Codein found in:

A-Z Index: